566-97-2
566-97-2
Chemical Structure
Zymostenol
Synonym(s): 5a-Cholest-8-en-3b-ol
- CAS No.: 566-97-2
- Formula:C27H46O
- Molecular Weight:386.65
IUPAC Name: (3S,5S,10S,13R,14R,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,5,6,7,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol
InChIKey: QETLKNDKQOXZRP-XTGBIJOFSA-N
SMILES: CC(C)CCC[C@@H](C)[C@H]1CC[C@@]2([H])C(CC[C@@]3([H])C[C@@H](O)CC[C@]43C)=C4CC[C@]12C
Biological Activity: Zymostenol (5a-Cholest-8-en-3b-ol) is a late-stage precursor in the biosynthesis of cholesterol. Zymostenol is a RORγ agonist (EC50: 1 μM)[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Zymostenol | 99.33% | Zymostenol (5a-Cholest-8-en-3b-ol) is a late-stage precursor in the biosynthesis of cholesterol. Zymostenol is a RORγ agonist (EC50: 1 μM). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Zymostenol (Standard) | ≥98% | Oxyphenbutazone (monohydrate) (Standard) is the analytical standard of Oxyphenbutazone (monohydrate). This product is intended for research and analytical applications. Oxyphenbutazone monohydrate is a Phenylbutazone (HY-B0230) metabolite, with anti-inflammatory effect. Oxyphenbutazone monohydrate is an orally active non-selective COX inhibitor. Oxyphenbutazone monohydrate selectively kills non-replicating Mycobaterium tuberculosis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Zymostenol-d7 | 99.9% | Zymostenol-d7 is deuterium labeled 5a-Cholest-8-en-3b-ol. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Hu X, et al. Sterol metabolism controls T(H)17 differentiation by generating endogenous RORγ agonists. Nat Chem Biol. 2015 Feb;11(2):141-7. [Content Brief]
- [2]. Hubler Z, et al. Accumulation of 8,9-unsaturated sterols drives oligodendrocyte formation and remyelination. Nature. 2018 Aug;560(7718):372-376. [Content Brief]
- [3]. Payré B, et al. Microsomal antiestrogen-binding site ligands induce growth control and differentiation of human breast cancer cells through the modulation of cholesterol metabolism. Mol Cancer Ther. 2008 Dec;7(12):3707-18. [Content Brief]
